Monitor and analyze global clinical trials with endpoint analysis, competitor tracking, and enrollment assessment.
The Clinical Trial Intelligence Agent continuously monitors and analyzes global clinical trial data to provide actionable insights for R&D, medical affairs, and commercial teams.
This agent integrates data from clinicaltrials.gov, EudraCT, and other global registries to deliver comprehensive trial intelligence in real-time.
Analyze primary and secondary endpoints, surrogate markers, and regulatory acceptance patterns across trials.
Monitor competitor trial progress, design choices, and performance metrics in real-time.
Track enrollment rates, site performance, and patient recruitment strategies across trials.
Analyze inclusion/exclusion criteria, patient demographics, and stratification factors.
Comprehensive mapping of ongoing and completed trials across therapeutic areas and geographies.
Instant notifications on trial status changes, new initiations, and competitor movements.
Evaluate competitive trial landscape and endpoint selection to support portfolio investment decisions.
Benchmark against competitor trial designs to optimize endpoint selection and patient population criteria.
Analyze historical site performance and enrollment patterns to optimize site selection for new trials.
Monitor competitor trial progress and anticipate market entry timelines for competitive products.
Simply ask questions in natural language, and the Clinical Trial Intelligence Agent will analyze trial data and provide insights:
"What are the primary endpoints used in Phase 3 CAR-T trials?"
Agent Response: Based on analysis of 47 Phase 3 CAR-T trials, the most common primary endpoints are: Overall Response Rate (ORR) - 68%, Complete Response Rate (CRR) - 15%, Progression-Free Survival (PFS) - 12%, and Event-Free Survival (EFS) - 5%. The choice varies by indication and regulatory requirements...
"How is Novartis' Kymriah trial enrollment progressing?"
Agent Response: Kymriah trials are showing strong enrollment with an average of 85% of target enrollment achieved across active trials. Key performing sites include MD Anderson (92%), Memorial Sloan Kettering (89%), and European sites averaging 78%...
24/7 monitoring of global trial databases with instant updates.
Access to all major trial registries and databases worldwide.
Machine learning for pattern recognition and predictive insights.
Ask questions in plain English, get instant answers.
Clear recommendations backed by data and expert analysis.
Works with other agents for comprehensive intelligence.
Start using the Clinical Trial Intelligence Agent today to transform your trial analysis workflow.